Antibiotic Therapy for Intra-Abdominal Infections

Recommended Treatment Regimens

The Infectious Diseases Society of America recommends piperacillin-tazobactam as single-agent therapy for high-severity community-acquired intra-abdominal infections 1, 2, 3
The Infectious Diseases Society of America recommends piperacillin-tazobactam as single-agent therapy for pediatric community-acquired intra-abdominal infections 1, 2
The Infectious Diseases Society of America recommends piperacillin-tazobactam as monotherapy for empiric coverage of health care-associated intra-abdominal infections 4, 5
The Infectious Diseases Society of America recommends piperacillin-tazobactam as single-agent therapy for severe biliary infections 4, 5

Metronidazole is combined with cefazolin, cefuroxime, ceftriaxone, cefotaxime, ciprofloxacin, or levofloxacin for mild-to-moderate community-acquired infections 1, 2, 3
Metronidazole is combined with cefepime, ceftazidime, ciprofloxacin, or levofloxacin for high-severity infections requiring anti-pseudomonal coverage 1, 2, 3
Metronidazole is combined with ceftriaxone for necrotizing fasciitis 6
Combination therapy uses cefepime or ceftazidime along with metronidazole for neutropenic enterocolitis 7

There is no safety concern or drug interaction preventing concurrent use of metronidazole and piperacillin-tazobactam 1, 2, 6
Adding metronidazole to piperacillin-tazobactam provides no additional clinical benefit for anaerobic coverage 6
Using both agents increases unnecessary antibiotic exposure, cost, and potential for adverse effects 1
The practice contradicts antimicrobial stewardship principles by using broader therapy than needed 8